Waters Corporation
WAT
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $30.6B
$409.38
▼ -1.01%
P/E
102.09
Mkt Cap
$30.6B
52-Wk Range
$282.77–$426.22
52-Week Range
$282.77 - $426.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 32.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced proprietary technologies
- Comprehensive analytical workflow solutions
- Broad global customer base
- Strong research and development capabilities
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Increasing pharmaceutical research spending
Value
Fairly valued vs Life Sciences Tools peers
Momentum
Strong
+12.7% over 3m
Quality
Strong
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying WAT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 4, 2026
Reported EPS of $3.05 vs $3.01 consensus (+1.3% surprise). Revenue of $1.6B vs $1.6B expected (+1.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1.3%
Revenue trend · last 8Q
—
+6%
+4%
+9%
+8%
+7%
+91%
+113%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$740.3M
$872.7M
$661.7M
$771.3M
$799.9M
$932.4M
$1.3B
$1.6B
Margins · last 8Q
Gross
44.6%
Operating
-5.2%
Profit
-8.3%
Wall Street consensus
12 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Piper Sandler · Aug 27, 2026
vs Industry
How WAT stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related